Cullen/Frost Bankers, Inc. Biogen Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 86 shares of BIIB stock, worth $12,156. This represents 0.0% of its overall portfolio holdings.
Number of Shares
86
Previous 50
72.0%
Holding current value
$12,156
Previous $9,000
44.44%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding BIIB
# of Institutions
990Shares Held
131MCall Options Held
1.12MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.36 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$2.27 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.06 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.04 Billion0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY5.26MShares$743 Million0.08% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.4B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...